TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05683275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM
Description: IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT
Description: ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
Study: NCT06492720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) treatment
Description: The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound (FUS) treatment
Description: The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.
Study: NCT06095284

Intervention type: OTHER
Intervention: Post-Extraction Phase
Description: Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation
Study: NCT06249984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04523792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBLOCADE
Description: SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
Study: NCT06018116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT06249984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test
Study: NCT06428149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midline interproximal soft-tissue incision
Description: Firstly, the marginal tissue will be elevated around the periodontal defect, through the tunneling of the tissues, entering through the gingival sulcus and the periodontal pocket of the teeth involved in the defect periodontal. Once the marginal tissues have been disinserted to full thickness, the soft supra-alveolar component of the defect to be reconstructed will be stretched, in a buccal direction, with a blunt instrument, applying pressure on the lingual aspect. Visualizing the midpoint of the interproximal tissue, the papilla will be dissected at its midpoint, entering through the mesial aspect, with the scalpel blade perpendicular to the central axis of the teeth.
Study: NCT06249984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test
Study: NCT06428149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marginal approach by palatal incision
Description: First, an incision will be made in the palatal aspect of the interproximal papilla, at the base of the papilla, parallel to the axis of the tooth until touching the palatine alveolar crest, in order to detach and move the papilla from its base, attached to the vestibular flap. From the palatal incision the interproximal tissue will be elevated towards the buccal until the buccal bone crest is exposed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgical technique
Description: The defect will be accessed through an incision at the base of the papilla on the vestibular aspect. Depending on the anatomy of the interproximal space, two types of incisions will be made: simplified papilla preservation flap (SPPF) when the width of the interproximal space is equal to or less than 2 mm, or modified papilla preservation technique (MPPT) when the width is greater than 2 millimeters. The interproximal incision will extend intrasulcular on the lingual and buccal aspect of the teeth adjacent to the defect, and mesio-distally it will extend as necessary to allow access to the defect and its debridement. The papilla will move from its base towards the palatine.
Study: NCT06249984

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Carbon Monoxide Measurement
Description: Undergo CO test

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless Tobacco Use
Description: Use moist snuff

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless Tobacco Use
Description: Use moist snuff

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless Tobacco Use
Description: Use moist snuff
Study: NCT06306391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous naloxone
Description: Nyoxid 1.8 mg nasal spray, solution in single-dose container. Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Description: Naloxone Kern Pharma 1 mg in total (from 0.4 mg/mL injectable solution). Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
Study: NCT05539794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle and physical exercise
Description: the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions.
Study: NCT06249984

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless Tobacco Use
Description: Use moist snuff

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smokeless Tobacco Use
Description: Use moist snuff
Study: NCT05336097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pathways to Empowerment
Description: Pathways to Empowerment (PTE) is a program for person-centered intervention. PTE is rooted in the Strengths Model by Rapp and Goscha (2011), and in the Social Quality Approach as described by Van der Maesen and Walker (2005). The general aim of PTE is to improve the quality of the daily lives of persons who experience loss of control in their lives by focusing on their strengths and stimulating their personal agency, participation in society, and self-direction in life. The main task of professionals is to help create the conditions in which growth and recovery are likely to occur.
Study: NCT06249984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05348850

Intervention type: DEVICE
Intervention: Tensiomayography (TMG)
Description: Quadriceps muscle contractile properties will be assessed using tensiomayography
Study: NCT05849376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emergent Multi-Class Imitation Training
Description: Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments.A minimum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 20-25 min to conduct. Each session will consist of the instructor presenting imitation training trials and probe trials. During baseline sessions, participants will not receive rewards for correct imitation. During training, participants will receive rewards for correct imitation and evidence-based teaching strategies that are commonly employed in applied behavior analysis therapy will be used to help participants learn how to imitate new responses. Novel probe trials will be embedded throughout all sessions to continuously evaluate the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Emergent Multi-Class Imitation Training
Description: Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments.A minimum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 20-25 min to conduct. Each session will consist of the instructor presenting imitation training trials and probe trials. During baseline sessions, participants will not receive rewards for correct imitation. During training, participants will receive rewards for correct imitation and evidence-based teaching strategies that are commonly employed in applied behavior analysis therapy will be used to help participants learn how to imitate new responses. Novel probe trials will be embedded throughout all sessions to continuously evaluate the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
Study: NCT05500846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Visual Ice Cryoablation System
Description: Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
Study: NCT05920096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes specialist nurse-led multi-component smoking cessation intervention
Description: Aims to:~* inform participants on the association between smoking and diabetic complications;~* motivate and encourage smokers to quit;~* support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)
Description: A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
Study: NCT05327530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6223
Description: Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255
Description: Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Study: NCT04538352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Medication for type 2 diabetes management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Medication for type 2 diabetes management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Medication for type 2 diabetes management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Medication for type 2 diabetes management (rapid-acting)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Medication for type 2 diabetes management (rapid-acting)
Study: NCT06140407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Receive Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Receive Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Receive Etoposide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Receive Pembrolizumab by IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Computed Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo Positron Emission Tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo Radiation Therapy
Study: NCT05141526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-restrictive satiating intervention
Description: Diet group containing satiating foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional restrictive intervention + non-restrictive satiating intervention
Description: Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: This group will receive minimal healthy guidelines
Study: NCT06005506

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic fiber
Description: Moradyn active prebiotic fiber product

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber
Description: Fibregum non-active fiber product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Defense Plus probiotic complex

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Defense Plus probiotic complex
Study: NCT04665544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.
Description: The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques.
Study: NCT05114889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BSI-045B
Description: BSI-045B will be administered weekly, subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BSI-045B
Description: BSI-045B will be administered weekly, subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BSI-045B
Description: BSI-045B will be administered weekly, subcutaneously
Study: NCT04850911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention (placebo)
Description: Placebo injection (0.9% sodium chloride)
Study: NCT05191329

Intervention type: DIAGNOSTIC_TEST
Intervention: TPQue Greek version, NEI-VFQ-25 Greek version
Description: Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
Study: NCT06271655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPOTFIRE R Panel
Description: The intervention involves the use of a rapid point-of-care multiplex PCR test (Spotfire) to identify etiology of patients with ARI. Specimen samples will be collected by research staff at the time of ED presentation. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. The device will be in the ED to facilitate testing and accelerate delivery of diagnostic results to clinicians. The time when the provider receives the results will be recorded to evaluate the incorporation of results in clinical decision making.
Study: NCT06560034

Intervention type: DEVICE
Intervention: VicorderCS
Description: 1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device;~2. Data Station (VCS-DAT-1000) for data collection and analysis
Study: NCT06348888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Capsule, 100 mg, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Tablet, 100 mg, 200mg and 300mg, oral.
Study: NCT05462080

Intervention type: DIAGNOSTIC_TEST
Intervention: Ceraxis product
Description: All patients will have their symptoms evaluated using the Ceraxis product
Study: NCT06292975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Vigorous intensity aerobic interval exercise
Description: 7-weeks course of aerobic and resistance exercise, delivered 2 weeks before neoadjuvant radiotherapy (NART), 1 week of NART and 4 weeks post NART.
Study: NCT05614063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study: NCT04862676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes are spent during the compression and decompression phases and subjects have 5-10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.